Ginkgo Bioworks (DNA) Competitors $12.51 +0.75 (+6.36%) Closing price 03:59 PM EasternExtended Trading$12.65 +0.14 (+1.14%) As of 07:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock DNA vs. TWST, MENS, KYMR, SRRK, BHC, XENE, AMRX, HCM, RARE, and NAMSShould you be buying Ginkgo Bioworks stock or one of its competitors? The main competitors of Ginkgo Bioworks include Twist Bioscience (TWST), Jyong Biotech (MENS), Kymera Therapeutics (KYMR), Scholar Rock (SRRK), Bausch Health Cos (BHC), Xenon Pharmaceuticals (XENE), AMNEAL PHARMACEUTICALS (AMRX), HUTCHMED (HCM), Ultragenyx Pharmaceutical (RARE), and NewAmsterdam Pharma (NAMS). These companies are all part of the "pharmaceutical products" industry. Ginkgo Bioworks vs. Its Competitors Twist Bioscience Jyong Biotech Kymera Therapeutics Scholar Rock Bausch Health Cos Xenon Pharmaceuticals AMNEAL PHARMACEUTICALS HUTCHMED Ultragenyx Pharmaceutical NewAmsterdam Pharma Twist Bioscience (NASDAQ:TWST) and Ginkgo Bioworks (NYSE:DNA) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, media sentiment, risk, profitability and institutional ownership. Which has higher valuation & earnings, TWST or DNA? Twist Bioscience has higher revenue and earnings than Ginkgo Bioworks. Twist Bioscience is trading at a lower price-to-earnings ratio than Ginkgo Bioworks, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTwist Bioscience$362.27M4.76-$208.73M-$1.45-19.72Ginkgo Bioworks$227.04M3.26-$547.03M-$5.86-2.13 Is TWST or DNA more profitable? Twist Bioscience has a net margin of -23.51% compared to Ginkgo Bioworks' net margin of -136.56%. Twist Bioscience's return on equity of -29.03% beat Ginkgo Bioworks' return on equity.Company Net Margins Return on Equity Return on Assets Twist Bioscience-23.51% -29.03% -21.77% Ginkgo Bioworks -136.56%-43.25%-22.29% Does the media prefer TWST or DNA? In the previous week, Twist Bioscience had 5 more articles in the media than Ginkgo Bioworks. MarketBeat recorded 9 mentions for Twist Bioscience and 4 mentions for Ginkgo Bioworks. Twist Bioscience's average media sentiment score of 1.11 beat Ginkgo Bioworks' score of 0.16 indicating that Twist Bioscience is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Twist Bioscience 6 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ginkgo Bioworks 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk and volatility, TWST or DNA? Twist Bioscience has a beta of 2.36, indicating that its stock price is 136% more volatile than the S&P 500. Comparatively, Ginkgo Bioworks has a beta of 1.5, indicating that its stock price is 50% more volatile than the S&P 500. Do analysts prefer TWST or DNA? Twist Bioscience currently has a consensus price target of $49.40, indicating a potential upside of 72.79%. Ginkgo Bioworks has a consensus price target of $8.50, indicating a potential downside of 32.04%. Given Twist Bioscience's stronger consensus rating and higher probable upside, equities research analysts clearly believe Twist Bioscience is more favorable than Ginkgo Bioworks.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Twist Bioscience 1 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.73Ginkgo Bioworks 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Do institutionals & insiders hold more shares of TWST or DNA? 78.6% of Ginkgo Bioworks shares are owned by institutional investors. 3.0% of Twist Bioscience shares are owned by company insiders. Comparatively, 9.7% of Ginkgo Bioworks shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. SummaryTwist Bioscience beats Ginkgo Bioworks on 13 of the 16 factors compared between the two stocks. Get Ginkgo Bioworks News Delivered to You Automatically Sign up to receive the latest news and ratings for DNA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DNA vs. The Competition Export to ExcelMetricGinkgo BioworksMED IndustryMedical SectorNYSE ExchangeMarket Cap$740.47M$3.09B$5.82B$21.17BDividend YieldN/A2.23%3.84%3.59%P/E Ratio-2.1321.1431.1529.15Price / Sales3.26399.83475.5754.92Price / CashN/A43.0937.1523.84Price / Book1.218.079.115.45Net Income-$547.03M-$54.72M$3.26B$992.10M7 Day Performance-4.95%2.62%2.11%2.62%1 Month Performance-6.52%7.63%5.12%2.51%1 Year Performance50.79%13.11%31.25%12.94% Ginkgo Bioworks Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DNAGinkgo Bioworks0.9069 of 5 stars$12.51+6.4%$8.50-32.0%N/A$740.47M$227.04M-2.13640TWSTTwist Bioscience4.1868 of 5 stars$28.02-0.4%$49.40+76.3%-40.0%$1.69B$312.97M-19.32990Positive NewsMENSJyong BiotechN/A$41.22-7.9%N/AN/A$3.13BN/A0.0031News CoverageKYMRKymera Therapeutics3.0894 of 5 stars$43.62+2.3%$59.11+35.5%-12.3%$3.12B$47.07M-12.57170SRRKScholar Rock4.5802 of 5 stars$31.52+0.4%$45.14+43.2%+273.5%$3.03B$33.19M-10.83140News CoverageAnalyst ForecastBHCBausch Health Cos4.3462 of 5 stars$8.02-3.8%$9.00+12.2%+28.7%$2.97B$9.63B30.8520,700Analyst RevisionXENEXenon Pharmaceuticals2.0966 of 5 stars$37.82-1.1%$53.20+40.7%-2.5%$2.92B$9.43M-10.65210Options VolumeAMRXAMNEAL PHARMACEUTICALS3.3522 of 5 stars$9.26-2.0%$11.60+25.3%+17.1%$2.91B$2.79B926.938,100News CoveragePositive NewsInsider TradeHCMHUTCHMED2.736 of 5 stars$16.43-0.1%$28.00+70.4%-10.2%$2.87B$630.20M0.001,811RAREUltragenyx Pharmaceutical4.7233 of 5 stars$29.70+0.0%$81.50+174.4%-48.3%$2.86B$560.23M-5.371,294News CoverageNAMSNewAmsterdam Pharma3.6216 of 5 stars$25.40+1.3%$41.20+62.2%+50.2%$2.86B$45.56M-15.684 Related Companies and Tools Related Companies Twist Bioscience Competitors Jyong Biotech Competitors Kymera Therapeutics Competitors Scholar Rock Competitors Bausch Health Cos Competitors Xenon Pharmaceuticals Competitors AMNEAL PHARMACEUTICALS Competitors HUTCHMED Competitors Ultragenyx Pharmaceutical Competitors NewAmsterdam Pharma Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:DNA) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredThe stealth altcoin the financial world is underestimatingThis DeFi project could soar next When altcoin season fully kicks in—which the data suggests is happening R...Crypto 101 Media | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredA grave, grave error.Nvidia just shattered records—hitting $4 trillion in valuation faster than any company in history. But one ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ginkgo Bioworks Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ginkgo Bioworks With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access